Evidence map›Paper›PMID 40011874›Full record

ArticleJournal of translational medicine2025

ChromInst: a multicentre evaluation of robustness in aneuploidy and structural rearrangement testing.

Wenbin Niu, Shanjun Dai, Linli Hu, Yao He, Xiqian Zhang, Xia Xue, Li Wu, Haixia Jin, Dun Liu, Keya Tong and 12 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Wenbin Niu *Center for Reproductive Medicine, Henan Key Laboratory of Reproduction and Genetics, The First Affliated Hospital of Zhengzhou University, Zhengzhou, China.
Shanjun Dai *Center for Reproductive Medicine, Henan Key Laboratory of Reproduction and Genetics, The First Affliated Hospital of Zhengzhou University, Zhengzhou, China.
Linli Hu *Center for Reproductive Medicine, Henan Key Laboratory of Reproduction and Genetics, The First Affliated Hospital of Zhengzhou University, Zhengzhou, China.
Yao HeChongqing Key Laboratory of Human Embryo Engineering, Center for Reproductive Medicine, Women and Children's Hospital of Chongqing Medical University, Chongqing, China.
Xiqian ZhangReproductive Medical Center, Guangdong Women and Children Hospital, Guangzhou, China.
Xia XueThe Assisted Reproduction Center, Northwest Women's and Children's Hospital, Xian, China.
Li WuCenter for Reproductive Medicine, Tongji Hospital, Tongji Medicine College, Huazhong University of Science and Technology, Wuhan, China.
Haixia JinCenter for Reproductive Medicine, Henan Key Laboratory of Reproduction and Genetics, The First Affliated Hospital of Zhengzhou University, Zhengzhou, China.
Dun LiuReproductive Medical Center, Guangdong Women and Children Hospital, Guangzhou, China.
Keya TongChongqing Key Laboratory of Human Embryo Engineering, Center for Reproductive Medicine, Women and Children's Hospital of Chongqing Medical University, Chongqing, China.
Senlin ShiCenter for Reproductive Medicine, Henan Key Laboratory of Reproduction and Genetics, The First Affliated Hospital of Zhengzhou University, Zhengzhou, China.
Li TianThe Assisted Reproduction Center, Northwest Women's and Children's Hospital, Xian, China.
Yifan ZhouCenter for Reproductive Medicine, Tongji Hospital, Tongji Medicine College, Huazhong University of Science and Technology, Wuhan, China.
Guidong YaoCenter for Reproductive Medicine, Henan Key Laboratory of Reproduction and Genetics, The First Affliated Hospital of Zhengzhou University, Zhengzhou, China.
Sijia LuYikon Genomics Co., Ltd., Shanghai, China.
Yaxin YaoYikon Genomics Co., Ltd., Shanghai, China.
Dunmei ZhaoYikon Genomics Co., Ltd., Shanghai, China.
Lei JinCenter for Reproductive Medicine, Tongji Hospital, Tongji Medicine College, Huazhong University of Science and Technology, Wuhan, China. ljin@tjh.tjmu.edu.cn.
Haiyan BaiThe Assisted Reproduction Center, Northwest Women's and Children's Hospital, Xian, China. bhy1212@126.com.
Fenghua LiuReproductive Medical Center, Guangdong Women and Children Hospital, Guangzhou, China. liushine2006@163.com.
Dongyun LiuChongqing Key Laboratory of Human Embryo Engineering, Center for Reproductive Medicine, Women and Children's Hospital of Chongqing Medical University, Chongqing, China. dongyunliu@163.com.
Yingpu SunCenter for Reproductive Medicine, Henan Key Laboratory of Reproduction and Genetics, The First Affliated Hospital of Zhengzhou University, Zhengzhou, China. syp2008@vip.sina.com.ORCID 0000-0003-3783-6509

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreimplantation genetic testing for aneuploidy and for chromosomal structural rearrangement (PGT-A/-SR) can improve clinical pregnancy rates and live birth rates, and shorten the time to pregnancy. The large-scale statistics on their efficacy and accuracy across different centres, as well as the frequency of abnormalities for each chromosome, will provide a valuable supplement to previous research.

methodsPatients who had PGT-A or -SR procedures at five reproductive centres from 2018 to 2022 were recruited based on PGT-A/-SR indications. ChromInst and next-generation sequencing (NGS)-based PGT technology were utilised to detect copy number variations in embryos. Sequencing data metrics such as median absolute pairwise difference (MAPD) and detection success rate were analysed to evaluate the robustness of ChromInst. To assess ChromInst's accuracy, the chromosomal results from amniocentesis, abortions, and neonatal blood was as the gold standard for negative PGT results; the fluorescence in situ hybridisation (FISH), which was performed on embryos that identified as aneuploid through PGT was as the gold standard for positive PGT results. The frequency of abnormalities in each chromosome was also explored in aneuploid embryos.

resultsA total of 5,730 embryos were tested from 1,015 patients in the study, 391 of whom had PGT-A and 624 of whom had PGT-SR. 99.5% (5,699/5,730) of the embryos had an NGS sequencing MAPD value < 0.25, and 99.3% (5,689/5,730) of the embryos achieved successful PGT-A/-SR detection. Compared with the gold standard, the concordance of negative PGT-A/-SR results was 99.8% (506/507), and that of positive results was 99.8% (1,123/1,125). The euploidy rate in the PGT-A population was 45.9% (981/2,135). The proportion of euploid + balanced embryos was highest among couples with non-polymorphic inversions (44.6%, 152/341), followed by those with Robertsonian translocations (39.0%, 293/752), and lowest among those with reciprocal translocations (22.5%, 483/2,143). Chromosomes 16, 22, and 15 had the highest frequency of autosomal trisomies among the embryos from PGT-A patients, while chromosomes 16, 22, and 21 had the highest frequency of monosomies. High-frequency chromosomes with de novo chromosomal abnormalities for trisomies and monosomies were similar in the PGT-SR patients to those in the PGT-A patients.

conclusionsChromInst-based PGT-A/-SR could accommodate operational variations among different clinical centres, ensuring accurate results through robust and stable detection performance. Prior to PGT-A/-SR, more trustworthy data could be provided to support the genetic counselling.

Indexed as

AneuploidyGene RearrangementGenetic TestingPreimplantation DiagnosisAdultChromosome AberrationsDNA Copy Number VariationsFemaleHigh-Throughput Nucleotide SequencingHumansIn Situ Hybridization, FluorescencePregnancyAccuracyChromInstPreimplantation genetic testing for aneuploidy (PGT-A)Preimplantation genetic testing for chromosomal structural rearrangement (PGT-SR)Robust

Identifiers

PMID40011874
PMCPMC11863937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.